Viemed Healthcare, Inc. (VMD) - 2025 Annual Report Summary
Business Context and Reporting Period
This summary covers the Form 10-K for Viemed Healthcare, Inc. for the fiscal year ended December 31, 2025. Viemed is a provider of home medical equipment (HME) and post-acute healthcare services in the United States, focusing on respiratory care, chronic disease management, and women's health. The company operates in all 50 states, utilizing a technology-enabled, home-based clinical care model to reduce hospital readmissions and lower total healthcare costs.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $270.3 million | $224.3 million | +20.5% |
| Net Income (Viemed) | $14.9 million | $11.3 million | +32.6% |
| Gross Profit Margin | 57.5% | 59.4% | -1.9 pts |
| Operating Income | $22.9 million | $17.9 million | +28.2% |
| Adjusted EBITDA | $51.4 million (Full Year) | $51.1 million (Full Year) | +0.6% |
| Cash & Equivalents | $13.5 million | $17.5 million | -22.9% |
| Total Debt (Outstanding) | $12.9 million | $4.6 million | +180% |
| Operating Cash Flow | $51.9 million | $39.1 million | +32.7% |
Note: Adjusted EBITDA is a non-GAAP measure. Full year 2025 Adjusted EBITDA calculated by summing quarterly figures provided in the filing ($18.2M + $16.1M + $14.3M + $12.8M).
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by a 62.7% increase in equipment and supply sales (due to the sleep resupply program and the Lehan Drugs acquisition) and a 9.8% increase in ventilator rental revenue.
- Acquisitions: Completed the acquisition of Lehan Drugs, Inc. on July 1, 2025, for approximately $29.2 million, adding maternal health services and expanding Midwest presence. This contributed to higher SG&A expenses and debt levels.
- Margin Compression: Gross margin decreased to 57.5% from 59.4% due to a shift in revenue mix toward categories with higher direct costs relative to ventilator rentals.
- Debt Utilization: Outstanding borrowings increased to $12.9 million (Term Loan) to fund the Lehan acquisition, up from $4.6 million in 2024. The Revolving Credit Facility was fully repaid by year-end.
- Share Repurchases: Completed a 2025 share repurchase program, buying back 1.98 million shares for $13.6 million. A new program authorizing up to 1.93 million shares was approved in March 2026.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management anticipates continued growth driven by the aging population, rising chronic disease incidence, and the industry shift toward home-based care. The company expects to leverage scale to improve operating efficiencies, though gross margins may fluctuate based on revenue mix. The company believes its current liquidity and credit facilities are sufficient to fund operations and growth for the next 12 months.
Key Risks & Contingencies:
- Regulatory Changes (CMS): A new National Coverage Determination (NCD) for non-invasive ventilation for COPD patients took effect in June 2025, establishing stricter medical necessity criteria that could impact patient access and reimbursement. Additionally, a temporary moratorium on new Medicare enrollments for certain DMEPOS suppliers was announced in February 2026, potentially delaying expansion or acquisitions.
- Reimbursement Pressure: Approximately 40% of revenue is derived from Medicare and Medicaid. Reductions in reimbursement rates or delays in payment cycles pose significant liquidity risks.
- Competitive Bidding: While current respiratory products are not subject to the next round of competitive bidding, future inclusion remains a risk.
- Supply Chain & Tariffs: Dependence on third-party suppliers exposes the company to potential cost increases and supply disruptions due to tariffs or trade policy changes.
Investor Verification Checklist
- CMS NCD Impact: Verify the actual impact of the June 2025 NCD on ventilator patient volumes and reimbursement rates in Q1 2026.
- Lehan Integration: Monitor the integration progress of Lehan Drugs, Inc., specifically regarding the realization of synergies and the impact on maternal health revenue.
- Debt Covenants: Confirm continued compliance with the 2022 Senior Credit Facilities covenants (Leverage Ratio & Fixed Charge Coverage) given the increased debt load.
- Share Repurchase Activity: Track execution of the new 2026 share repurchase program and its effect on cash reserves.
- Reimbursement Delays: Review Days Sales Outstanding (DSO) trends to assess any liquidity strain from delayed Medicare/Medicaid payments.